Seres Therapeutics, Inc.
MCRB
$7.76
-$0.20-2.51%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 1.93% | -90.76% | 39.60% | 181.43% | 62.09% |
| Total Depreciation and Amortization | -9.05% | -25.64% | -25.42% | -30.98% | -2.35% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -100.00% |
| Total Other Non-Cash Items | 5.79% | 103.98% | -43.47% | -59.55% | -88.80% |
| Change in Net Operating Assets | 81.67% | -21.43% | 106.63% | -27.96% | -95.76% |
| Cash from Operations | 62.17% | 106.36% | 66.62% | 176.37% | 18.14% |
| Capital Expenditure | 67.78% | 93.80% | -82.83% | 45.16% | 89.74% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 301.11% | -100.01% | -113.90% | 45.16% | 89.74% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 628.67% | -99.64% | -- | -93.71% | -72.98% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 628.67% | 100.06% | -- | -93.71% | -72.98% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 94.97% | 151.25% | 65.02% | 269.67% | 11.23% |